sertraline / Generic mfg. - LARVOL DELTA

CLINICALLY RELEVANT DRUG–DRUG INTERACTIONS BETWEEN ANTIDEPRESSANTS AND GASTROINTESTINAL MEDICATIONS: EVIDENCE FROM A SYSTEMATIC REVIEW AND FAERS ANALYSIS (UEGW 2026) - "Compared with reports involving either drug class alone, combined use was associated with a higher proportion of serious outcomes, particularly hospitalisation (40.4% vs. 29.8% and 24.8%, respectively).Disproportionality analyses identified robust signals for clinically relevant adverse events, particularly QT interval prolongation, across multiple antidepressant–acid-suppressive drug combinations, including fluvoxamine–pantoprazole, clomipramine–pantoprazole, fluoxetine–lansoprazole, citalopram–lansoprazole, and sertraline–pantoprazole. Clinically relevant drug–drug interactions between antidepressants and gastrointestinal medications were consistently identified across both the literature and real-world pharmacovigilance data. The findings highlight QT prolongation and neuropsychiatric disturbances as key safety concerns associated with commonly used combinations, particularly those involving acid-suppressive agents. These results underscore the importance of..."

Clinical • Review • CNS Disorders • Mental Retardation

Toward Precision Psychiatry: Sex- and Glutamate-Dependent Stress Vulnerability in DAT Transgenic Rats (Neuroscience 2026) - "In parallel, environmental and pharmacological interventions, including voluntary wheel running and sertraline treatment, were evaluated as potential modulators of vulnerability phenotypes...Emerging molecular data further suggest that alterations in glutamatergic signaling may contribute to these divergent trajectories.These findings support a model in which stress vulnerability emerges from interactions among genetic susceptibility, sex, and underlying neurobiological mechanisms rather than from environmental exposure alone. By identifying biologically distinct vulnerability profiles and their differential responsiveness to intervention, this DAT transgenic model provides a translational platform for the development of individualized therapeutic strategies and precision psychiatry approaches for stress-related disorders."

Preclinical • CNS Disorders • Mood Disorders • Psychiatry

Real-World Antidepressant Prescribing Patterns and Comparative Safety Outcomes of Commonly Prescribed Antidepressants in Patients with Depressive Disorder: A Multicenter OMOP-CDM Study. (PubMed, Pharmaceuticals (Basel)) - "Common adjunctive medications included trazodone (14.6%, n = 794) and quetiapine (14.0%, n = 761), though utilization varied across hospitals. While comparative safety profiles were broadly comparable across evaluated outcomes, the isolated QTc prolongation signal for sertraline warrants targeted external confirmation. Furthermore, trazodone and escitalopram cohorts should not be regarded as clinically interchangeable first-line options, supporting individualized, evidence-based antidepressant selection in routine clinical practice."

Journal • Real-world evidence • CNS Disorders • Depression • Mood Disorders • Psychiatry

CYP2C19 and CYP2D6 variation and serotonin reuptake inhibitor outcomes in obsessive-compulsive disorder: a systematic review. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "CYP2C19 and CYP2D6 genotypes have pharmacokinetic relevance for selected antidepressants, but available evidence does not establish that they predict or improve OCD-specific outcomes. Pharmacogenomic information may assist selected drug-specific decisions but cannot currently support a validated treatment algorithm for OCD."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • CYP2C19

Pharmacogenetic, Clinical, Prescribing, and Demographic Predictors of Sertraline Pharmacokinetics. (PubMed, Pharmaceutics) - "In a small exploratory subgroup analysis, patients with combined CYP2C19 and CYP2B6 poor-metabolizer status (n = 2) had sertraline concentrations exceeding 150 ng/mL. The study findings provide further insights into the relevance of CYP2C19 in sertraline pharmacokinetics."

Biomarker • Journal • PK/PD data • CYP2C19 • CYP2C9 • CYP3A4

The Beyond Ageing Project: A selective prevention trial using novel pharmacotherapies in an older age cohort at risk for depression (ANZCTR) - P3/4 | N=450 | Completed | Sponsor: University of Sydney | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Mood Disorders • Psychiatry

Targeting the Tumor, Tripping the Liver: A Rare Case of Neladalkib-Induced DILI (ACG 2026) - "Neladalkib was held and LFTs peaked (AST 6,594; ALT >5,000)...She received N-acetylcysteine (NAC) infusion and hemodiafiltration...The absence of viral markers and unremarkable liver imaging strongly point toward a drug-induced etiology; concurrent medications of colchicine and sertraline were likely non-contributors...Figure: Figure 1. DILI Resolution timeline by ALT, AST, Ammonia, and INRx10"

Clinical • Hepatology • Immunology • Infectious Disease • Liver Failure • Lung Cancer • Nephrology • Oncology • Septic Shock • Solid Tumor • ALK

A Disappearing Act: Vanishing Bile Duct Syndrome in Classical Hodgkin Lymphoma (ACG 2026) - "The patient was treated with nivolumab, cyclophosphamide, and mantle radiation, with ursodiol and sertraline for pruritus. D. Cytokeratin 7 immunostain highlights the small native bile duct and associated proliferating ductules (blue arrows), with prominent staining of intermediate hepatocytes (CK7, Ã200)."

Cholestasis • Classical Hodgkin Lymphoma • Fibrosis • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Immunology • Infectious Disease • Liver Cirrhosis • Liver Failure • Lymphoma • Primary Biliary Cholangitis • Pruritus • Pulmonary Disease

Comparative Efficacy and Tolerability of Pharmacological Agents for Cholestatic Pruritus in Primary Biliary Cholangitis: A Systematic Review and Network Meta-Analysis (ACG 2026) - "(c) Any adverse events: rifampin, sertraline, naltrexone, and linerixibat carried significantly higher adverse event rates versus placebo; nalfurafine 5 mg was the safest agent (P-score 0.82). Fourteen RCTs across 9 active treatment nodes were included. On continuous pruritus reduction, rifampin ranked first (SMD -4.21 [95% CI -7.12, -1.29]; P-score 0.90), followed by linerixibat (SMD -2.68 [-4.55, -0.80]; P-score 0.69) and naltrexone (SMD -2.62 [-4.73, -0.51]; P-score 0.68). For responder rate, rifampin led (RR 2.80 [1.29-6.05]), while linerixibat combined a significant responder rate (RR 1.69 [1.20-2.38]) with the highest P-score among well-powered trials (0.53)."

Retrospective data • Review • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

SSRI Use in Irritable Bowel Syndrome and Its Impact on Disease Outcomes: A Propensity-Matched Real-World Cohort Study (ACG 2026) - "Cohort 1 received an SSRI (sertraline, escitalopram, citalopram, fluoxetine, or paroxetine) within 1 year of diagnosis without concurrent TCA use. Post-matching cohorts were well-balanced (79.7% female, ~80% White). SSRI use was associated with lower functional symptom persistence (57.0% vs. 60.7%; RR 0.94, 95% CI 0.93-0.94; p< 0.001; median time-to-recurrence 589 vs."

Clinical • Real-world • Real-world evidence • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Mood Disorders • Ulcerative Colitis

The Impact of Common Medications on Male Fertility: An Updated Systematic Review. (PubMed, Andrology) - "In this updated review, evidence-based recommendations for clinical management and for possible fertility preservation or contraception in men of reproductive age receiving common acute or chronic medical treatment are provided, with the goal of making these data more readily available to medical staff."

Journal • Review • Infertility

PTSD treatment impacts on pain: secondary analysis of sertraline, prolonged exposure, and their combination. (PubMed, Eur J Psychotraumatol) - P4 | "Veterans with clinically significant baseline pain severity showed significant reduction in pain severity across time in all treatments, with no evidence for differential rates across treatments. While it is uncertain reduced pain was due to the treatments themselves, lower scores for all treatments suggest that PTSD-focused treatments may reduce pain even without a specific pain focus. Research is needed to isolate, if present, mechanistic pathways between PTSD treatment and pain reduction.Trial registration: ClinicalTrials.gov identifier: NCT01524133."

Clinical • Journal • CNS Disorders • Mood Disorders • Pain • Post-traumatic Stress Disorder

Individualized dlPFC-NAcc Modulation for Anhedonia in adMDD (clinicaltrials.gov) - P=N/A | N=88 | Completed | Sponsor: Xijing Hospital | Recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Neuropsychiatric adverse effects following switch to vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: early experience from a regional centre. (PubMed, J Cyst Fibros) - "Vanzacaftor-tezacaftor-deutivacaftor (VTD) is the newest triple-combination CFTR modulator, licensed as an alternative to elexacaftor-tezacaftor-ivacaftor (ETI)...Three had no prior psychiatric history; one had pre-existing depression on long-term sertraline that markedly worsened...These findings highlight the need for early mental health screening after VTD initiation and a low threshold for psychiatric review. All cases have been reported to the MHRA Yellow Card scheme."

Adverse events • Journal • CNS Disorders • Cystic Fibrosis • Depression • Genetic Disorders • Immunology • Psychiatry • Pulmonary Disease • Respiratory Diseases • Suicidal Ideation

Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system. (PubMed, Eur Arch Psychiatry Clin Neurosci) - "SSRIs showed homogeneous adverse event reporting patterns, with relatively few differences in disproportional reporting between individual drugs. These results reinforce the importance of continuous pharmacovigilance monitoring."

Adverse events • Journal • CNS Disorders • Mental Retardation • Pain • Psychiatry • ROR1

Rapid Eye Movement (REM)-Predominant Obstructive Sleep Apnea (OSA) Coexisting With and Initially Obscuring Narcolepsy Type 1: A Nine-Year Longitudinal Case Report. (PubMed, Cureus) - "Management included fixed-pressure CPAP at 8 cm H₂O, sertraline for cataplexy, and modafinil for EDS. When MSLT is required in a patient with OSA, effective treatment of OSA and adequate documentation of prior sleep are important for reliable interpretation. Management should address both OSA and narcolepsy and include periodic reassessment as the clinical phenotype evolves."

Journal • Cataplexy • CNS Disorders • Excessive Daytime Sleepiness • Narcolepsy • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

A Nanoimmunomodulator for Synergy Therapy of Pulmonary Cryptococcosis via Arousing Natural Killer Cells (ERS 2026) - "Methods A microfluidic strategy was employed to co-load sertraline and L-fucose into liposomes, yielding Lip@SER-FUC nano-immunomodulators...5. Conclusions Our results demonstrate that the as-synthesized Lip@SER-FUC can treat lung infection caused by the cryptococcus by combining drug therapy and activation of NK cells."

Immunomodulating • Infectious Disease • Respiratory Diseases

Pharmacological insights into fluvoxamine maleate: σ1 receptor agonism, multimodal mechanisms, and therapeutic repositioning. (PubMed, Curr Opin Pharmacol) - "Fluvoxamine demonstrates one of the highest affinities for σ1R among SSRIs, exceeding those of sertraline and fluoxetine, via dissociating σ1R from BiP chaperones to improve protein refolding and cellular resilience. Preclinical experiments illustrate its inhibition of unfolded protein response indicators, reinstatement of glutamatergic transmission, and stimulation of parvalbumin interneurons, resulting in antipsychotic-like effects in schizophrenia and neuroprotection against ketamine-induced impairments...σ1R agonism is fundamental to its effectiveness in disorders caused by ER stress, such as schizophrenia and tardive dyskinesia, and in neuropsychiatric sequelae associated with protracted COVID. Clinical translation encounters obstacles in dose optimization and σ1R selectivity; yet, current studies highlight its multimodal efficacy in neurodegeneration, fibrosis, and psychopharmacology."

Journal • Review • CNS Disorders • Depression • Fibrosis • Immunology • Inflammation • Mood Disorders • Movement Disorders • Novel Coronavirus Disease • Obsessive-Compulsive Disorder • Psychiatry • Schizophrenia

QT interval prolongation in the coronary intensive care unit: prevalence, associated drugs and clinical-genetic risk factors. (PubMed, Can J Physiol Pharmacol) - "Proton pump inhibitors were the most commonly used QTc-prolonging drugs (96.1%), while QTcIP was most frequently observed among patients receiving sertraline; however, the number of exposed patients was small...These findings suggest that QTc prolongation in clinical practice may occur in the context of diverse clinical conditions and rare genetic variants. Careful clinical monitoring remains essential when initiating QTc-prolonging medications, particularly in patients with cardiovascular comorbidities."

Journal • Acute Coronary Syndrome • Cardiovascular • Critical care • Hypertension • Myocardial Infarction • KCNH2 • LMNA

A Study on the Efficacy of Vitamin D Supplementation in Adolescents with Unipolar Depression (ChiCTR) - P=N/A | N=134 | Recruiting | Sponsor: Southern Medical University Southern Hospital; Southern Medical University Southern Hospital

New trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Sertraline and the Risk of Serious Adverse Events (clinicaltrials.gov) - P=N/A | N=6893 | Active, not recruiting | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed ➔ Active, not recruiting | Trial completion date: Jan 2026 ➔ Dec 2027

Adverse events • Enrollment closed • Serious adverse event • Trial completion date • Chronic Kidney Disease • Nephrology • Renal Disease

LYMPHODEP: Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants (clinicaltrials.gov) - P=N/A | N=50 | Completed | Sponsor: Germans Trias i Pujol Hospital | Trial completion date: Jul 2027 ➔ Jul 2026 | Trial primary completion date: Dec 2026 ➔ Jun 2026 | Not yet recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

Intranasal delivery of sertraline hydrochloride enhanced brain concentration and antidepressant activity: A comparative pharmacokinetic and pharmacodynamic study. (PubMed, J Pharm Sci) - "Compared with oral administration, both polymeric and lipidic nanoparticles alleviate chronic unpredictable stress-induced depressive behaviour in mice, with solid lipid nanoparticles showing a slight edge over polymeric nanoparticles. Overall, intranasal nanoparticle systems improved brain availability and antidepressant response, with distinct performance differences between lipidic and polymeric carriers."

Journal • PK/PD data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Bovine Serum Albumin Nanoparticles Prepared with Genipin: Size Modulation, Encapsulation, and In Vitro Response. (PubMed, Nanomaterials (Basel)) - "The optimized BSA NPs were then used to encapsulate sertraline and 5-fluorouracil, achieving encapsulation efficiencies of 82% and 40%, respectively. In vitro assays performed on normal prostate epithelial cells (PNT-2) and prostate cancer cells (22Rv1) showed that the BSA NPs modulated drug-induced cytotoxicity relative to free drugs, indicating a formulation-dependent biological response. These findings highlight the potential of genipin-crosslinked BSA NPs as a versatile and sustainable platform for drug delivery in cancer therapy."

Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

The in vivo ECODSed assay: an optimised method for measuring cytochrome P450 activity in sediment-dwelling organisms. (PubMed, Environ Pollut) - "In both ECODSed7 and ECODSed14, the antidepressant sertraline (SER; CYP inhibitor) produced persistently lower activity (∼30% on average) than controls...The Quick assay offers rapid screening of chemical modulators, species responses, substrate suitability; ECODSed7 captures early phase induction dynamics; ECODSed14 reveals sustained metabolic responses under long term exposure. ECODSed advances CYP450 mediated activity assessment in sediment dwelling organisms, enabling rapid evaluations and deeper mechanistic insight into contaminant effects."

Journal • Preclinical